CBIO - Catalyst Biosciences, Inc.
| Previous Close | 6.01 |
| Open | 6.06 |
| Bid | 0.00 x 900 |
| Ask | 6.45 x 1800 |
| Day's Range | 5.91 - 6.28 |
| 52 Week Range | 5.91 - 11.44 |
| Volume | 42,812 |
| Avg. Volume | 172,914 |
| Market Cap | 72.576M |
| Beta (3Y Monthly) | 2.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.96 |
| Earnings Date | Aug 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2015-08-20 |
| 1y Target Est | 22.30 |
- GlobeNewswire
Catalyst Biosciences Announces Transition of Chief Financial Officer
Catalyst Biosciences, Inc. (CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from the Company to pursue another opportunity effective August 30, 2019. The Company is initiating a search for a successor. “Fletcher has been a valuable member of our management team and I thank him for his contributions over the past four years,” said Nassim Usman, Ph.D., chief executive officer of Catalyst.
- Simply Wall St.
How Should Investors Feel About Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Pay?
Nassim Usman became the CEO of Catalyst Biosciences, Inc. (NASDAQ:CBIO) in 2015. First, this article will compare CEO...
- GlobeNewswire
Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2019 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug.
- GlobeNewswire
Catalyst Biosciences to Host Key Opinion Leader Meeting on Next-Generation Subcutaneous Factor VIIa Marzeptacog Alfa (Activated) in Patients with Bleeding Disorders on August 15
Catalyst Biosciences, Inc. (CBIO), today announced that it will host a Key Opinion Leader (KOL) meeting on next-generation subcutaneous Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) in individuals with bleeding disorders on Thursday, August 15 in New York City. The event will feature presentations by KOLs Robert Klamroth, M.D., Ph.D., Vivantes Hospital, Berlin, Germany, and Steven W. Pipe, M.D., C. S. Mott Children's Hospital, Ann Arbor, MI.
- GlobeNewswire
Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update
Phase 2 trial of subcutaneously administered MarzAA met primary endpoint of reduction in annualized bleed rate demonstrating safety and clinical efficacy, with 90% reduction.
- Barrons.com
Round Robin, Hertz, Catalyst Biosciences and Other 13D Filings
Catalyst Biosciences is in the activist spotlight, under pressure to add two shareholder representatives to the board
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Sangamo Therapeutics, Inc . (NASDAQ: SGMO ...
- Simply Wall St.
If You Had Bought Catalyst Biosciences (NASDAQ:CBIO) Stock Three Years Ago, You'd Be Sitting On A 68% Loss, Today
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
- GlobeNewswire
Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis
Oral presentation of the final Phase 2 trial data of MarzAA for the treatment of hemophilia A or B with inhibitors Company to host investor call and webcast on Monday, July 8.
- GlobeNewswire
Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Jefferies 2019 Global Healthcare Conference at 2:30 p.m. EDT on Tuesday, June 4, 2019 in New York. Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address serious medical conditions for individuals who need new or better treatment options.
- GlobeNewswire
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation.
- GlobeNewswire
Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
Catalyst Biosciences, Inc. (CBIO), and Mosaic Biosciences today announced the presentation of new data on pegylated CB 2782 (CB 2782-PEG), Catalyst’s preclinical anti-C3 candidate being developed for the treatment of geographic atrophy (GA) associated dry age-related macular degeneration (dry AMD) at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28 - May 2, 2019. The poster, entitled: “Pegylated CB 2782: A Complement Factor C3-Inactivating Protease and Potential Long-Acting Treatment for Dry AMD,” was presented by Eric Furfine, Ph.D., Mosaic’s Head of Ophthalmology.
- GlobeNewswire
Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference
Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare Conference at 12:50 p.m. EDT on Tuesday, April 9, 2019 at the Westin Grand Central Hotel in New York. An archived webcast of the presentation can be accessed for 90 days from the Events and Presentations section on the Company’s website.
- GlobeNewswire
Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B
Catalyst Biosciences, Inc. (CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B. “The data from our Phase 1/2 clinical study demonstrated that DalcA is highly efficacious for the treatment of hemophilia B and can achieve Factor IX activity levels well above the 12% expected to prevent spontaneous bleeding,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “We anticipate that this Phase 2b study will further demonstrate DalcA’s safety and efficacy as a subcutaneous prophylactic treatment option.
- Simply Wall St.
Could The Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ownership Structure Tell Us Something Useful?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls Catalyst Biosciences, Inc. (NASDAQ:CBIO), then you'll have to look at the makeup of i...
- GlobeNewswire
Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)
Catalyst Biosciences, Inc. (CBIO) today announced that the European Commission has awarded orphan designation of its Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for the treatment of haemophilia B (with or without inhibitors). Catalyst has also completed dosing in the Phase 2 portion of the Phase 2/3 subcutaneous trial of MarzAA for the treatment of hemophilia A or B with inhibitors.
- GuruFocus.com
Catalyst Biosciences Inc (CBIO) Files 10-K for the Fiscal Year Ended on December 31, 2018
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is engaged in creating and developing novel medicines to address serious medical conditions. Catalyst Biosciences Inc had annual average EBITDA growth of 33.50% over the past five years.For the latest fiscal year the company reported a revenue of $0.01 million, a decrease of 99.4% from the previous year.
- GlobeNewswire
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update
Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical efficacy, with 90% reduction in bleeding Completed a full immunogenicity analysis.
- GlobeNewswire
Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 06, 2019 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to.
- GlobeNewswire
New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
Catalyst Biosciences, Inc. (CBIO), presented updated interim data from the Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) currently being developed for the treatment of hemophilia A or B with inhibitors. “The positive data from our clinical trial demonstrate clinical proof-of-concept for MarzAA as a subcutaneous treatment option for individuals with hemophilia A or B with inhibitors,” said Dr. Nassim Usman, chief executive officer of Catalyst. “To date, each participant in the trial has experienced a clinically significant reduction in annualized bleed rate and the percentage of days with bleeding, highlighting the potential for MarzAA as a safe and effective subcutaneous treatment to reduce spontaneous bleed rates and improve the quality of life of affected individuals.
- GlobeNewswire
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
Results show a four-fold reduction in bleeding time for CB 2679d-GT and a three-fold improvement in clotting activity when compared with an AAV-encoding Padua vector Data.
- GlobeNewswire
Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
Catalyst Biosciences, Inc., (CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Annual BIO CEO & Investor Conference, being held in New York City on February 11-12, 2019. To schedule a meeting with the Catalyst Biosciences management team at this conference, please contact LifeSci Advisors. Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications.
- GlobeNewswire
Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced oral and poster presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in Prague from February 6-8, 2019. Dr. Howard Levy, chief medical officer of Catalyst, will deliver an oral presentation on the most up to date data from the Company’s ongoing Phase 2/3 trial of marzeptacog alfa (activated) (MarzAA) for the treatment of hemophilia A or B with inhibitors.
- Simply Wall St.
Is Catalyst Biosciences, Inc.’s (NASDAQ:CBIO) Balance Sheet A Threat To Its Future?
Catalyst Biosciences, Inc. (NASDAQ:CBIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CBIO Read More...
